Performance of Contour Next® and Contour Plus Elite® BGMS in Arterial Blood Samples From Hospitalized Adults
Launched by ASCENSIA DIABETES CARE · Jul 5, 2022
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
This trial will evaluate the performance of both Contour Next BGMS and Contour Plus Elite BGMS using arterial blood from adult patients hospitalized in a Critical Care Unit (medical and surgical intensive care units (ICUs)). The investigational BGMS will be tested by a Point-of-Care (POC) operator in a clinical setting using residual arterial blood samples from adults who underwent prescribed arterial blood tests that were deemed necessary due to their medical conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who are at least 18 years old.
- • Residual Arterial blood samples collected from subjects hospitalized in a Critical Care Unit (medical and surgical intensive care units (ICUs)).
- • Sample blood volume must be sufficient to complete investigational testing procedures clinical laboratory testing.
- Exclusion Criteria:
- • - Residual arterial blood samples collected from subjects previously enrolled. and evaluated for this study.
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global leader in diabetes management, dedicated to improving the lives of people living with diabetes through innovative solutions and advanced technologies. With a strong commitment to research and development, Ascensia focuses on creating user-friendly products that enhance blood glucose monitoring and management. The company prioritizes patient-centric approaches, ensuring that their clinical trials and product offerings are aligned with the needs of individuals with diabetes. By collaborating with healthcare professionals and leveraging cutting-edge science, Ascensia aims to drive better health outcomes and empower patients in their diabetes journey.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Adelaide, South Australia, Australia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials